Mirum Pharmaceuticals Q2 sales rise, lifts outlook
MIRM•Pipeline and analyst context
Mirum said it targets NDA submission for volixibat in cholestatic pruritus due to PSC in H1 2027.
The company also expects topline results from Phase 3 studies for brelovitug in Q3 and Q4 2026.
The current average analyst rating on the shares is "buy", with 14 strong buy or buy recommendations, no hold and no sell or strong sell. The average consensus recommendation for the pharmaceuticals peer group is "buy".
Wall Street's median 12-month price target for Mirum Pharmaceuticals is $145.00, about 39% above its August 4 closing price of $104.33.
Q2 sales rise and outlook lifted
Mirum Pharmaceuticals said second-quarter net product sales rose 38% year over year to $176 million.
The company raised its 2026 net product sales guidance to $680 million-$700 million.
